Momenta Pharmaceuticals (Momenta Pharmaceuticals) EV-to-Revenue : 194.34 (As of May. 13, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Momenta Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Momenta Pharmaceuticals's enterprise value is $5,844.09 Mil. Momenta Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2020 was $30.07 Mil. Therefore, Momenta Pharmaceuticals's EV-to-Revenue for today is 194.34.

The historical rank and industry rank for Momenta Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

MNTA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.88 Med: 8.13 Max: 180.15
Current: 184.36

During the past 13 years, the highest EV-to-Revenue of Momenta Pharmaceuticals was 180.15. The lowest was 0.88. And the median was 8.13.

MNTA's EV-to-Revenue is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.38 vs MNTA: 184.36

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-13), Momenta Pharmaceuticals's stock price is $52.48. Momenta Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 was $0.28. Therefore, Momenta Pharmaceuticals's PS Ratio for today is 189.46.

Momenta Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Momenta Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Momenta Pharmaceuticals EV-to-Revenue Chart

Momenta Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

EV-to-Revenue

Get a 7-Day Free Trial

7.59

6.70

4.85

7.98

77.17

Momenta Pharmaceuticals Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
EV-to-Revenue	Get a 7-Day Free Trial															15.58	19.66	77.17	98.16	115.66

Competitive Comparison of Momenta Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Momenta Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Momenta Pharmaceuticals's EV-to-Revenue falls into.

Momenta Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Momenta Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	5844.089	/	30.072
	=	194.34

Momenta Pharmaceuticals's current Enterprise Value is $5,844.09 Mil.
Momenta Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $30.07 Mil.

Momenta Pharmaceuticals (NAS:MNTA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Momenta Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	52.48	/	0.277
	=	189.46

Momenta Pharmaceuticals's share price for today is $52.48.
Momenta Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.28.

Momenta Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Momenta Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Momenta Pharmaceuticals Inc (NAS:MNTA) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.momentapharma.com

Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.

Executives

Bruce Downey	director
Alejandra Carvajal	officer: Chief Legal Officer	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Jose-carlos Gutierrez-ramos	director	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Georges Gemayel	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Elizabeth Stoner	director	C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142
Santiago Arroyo	officer: SVP, Chief Medical Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Young Kwon	officer: Chief Financial & Bus. Officer	C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Ian Fier	officer: Chief Mfg and Program Officer	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Jo Ann Beltramello	officer: Chief HR and Inf. Officer	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Anthony M. Manning	officer: Chief Scientific Officer	C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Donna Roy Grogan	director	1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Agnieszka Cieplinska	officer: Chief Accounting Officer (PAO)	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Craig A Wheeler	director, officer: President & CEO